|
| |
| | | 62126 | | 27.12.2012 | | Novartis Pharma Schweiz AG | | | | | | | | | | | | | 07.16.10. | | | | 07.16.10. | | FI |
| | Seq.-Nr. | Präparat | Beschreibung | Galenische Form | ATC-Klassierung | |
|---|
| 01 | Jakavi 5 mg | Tabletten | Tabletten (Ruxolitinibum 5 mg) | L01EJ01 | PI | | 02 | Jakavi 15 mg | Tabletten | Tabletten (Ruxolitinibum 15 mg) | L01EJ01 | PI | | 03 | Jakavi 20 mg | Tabletten | Tabletten (Ruxolitinibum 20 mg) | L01EJ01 | PI | | 04 | Jakavi 10 mg | Tabletten | Tabletten (Ruxolitinibum 10 mg) | L01EJ01 | PI |
|
|
|
